CXCR3 and neoplasm: Similarly, the frequency of CXCR3 was significantly higher on tumor-infiltrating CD8+ T lymphocytes than their circulating counterparts (44.52 ± 23.44% vs. 11.62 ± 9.86%, p < 0.0001) (Figure 4A and 4B).